Alterity Therapeutics Limited ADR (ATHE)
NASDAQ: ATHEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATHE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.02M
- EPS (TTM)
- -$0.90
- Dividend yield
- None
- 52-week range
- 1.52 – 5.89
- Day range
- 1.52 – 1.64
- Volume / Avg
- 20.24K / 89.63K
- Beta
- —
- Shares outstanding
- 19.09M
52-week range
ATHE stock today
Shares of Alterity Therapeutics (ATHE) finished lower on Nov 20 at $1.52, a drop of 8.16% or $0.135 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.24K shares changing hands, about 23% of the average daily volume. At this level, ATHE sits near the bottom of its 52-week range of $1.52 to $5.89: 74.2% below the high, set on Jul 6, 2026 and 0.0% above the low.
ATHE is down 50.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.7%. Alterity Therapeutics has posted a net loss over the last twelve months (EPS of -$0.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alterity Therapeutics
Company profileAlterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David A. Stamler M.D.
- Headquarters
- Melbourne, VIC
- Employees
- 11
- Website
- alteritytherapeutics.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$13.25+771.71%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ATHE news
All ATHE news- Alterity Therapeutics Limited Appoints BDO Audit Pty Ltd as Successor Auditor Effective November 20, 2026Nasdaq
- Alterity Therapeutics Limited Reports FDA Alignment on Phase 3 Trial Design and A$41.3 million Cash BalanceNasdaq
- Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare ConferenceGlobeNewswire
- Alterity Therapeutics Limited - Depositary Receipt Price Target Increased by 12.50% to $8.89Nasdaq
- Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate UpdateGlobeNewswire
- Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceGlobeNewswire
Alterity Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs ATHE |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs ATHE |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs ATHE |
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs ATHE |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs ATHE |
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs ATHE |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs ATHE |
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs ATHE |
Indexes, lists and sector
Alterity Therapeutics stock FAQ
What is Alterity Therapeutics's stock price today?
ATHE last traded at $1.52 as of Nov 20, 4:00 PM EST, down 8.16% on the day. Prices are delayed at least 15 minutes.
Does Alterity Therapeutics pay a dividend?
No. Alterity Therapeutics does not currently pay a regular cash dividend.
Who is Alterity Therapeutics's CEO?
Dr. David A. Stamler M.D. is the chief executive officer of Alterity Therapeutics Limited ADR, which has about 11 employees.
Has ATHE ever split its stock?
Yes. The most recent ATHE stock split was a 1-for-10 split on Jan 9, 2023, one of 2 splits on record.
What is the ATHE 52-week high?
The 52-week high for ATHE is $5.89 and the 52-week low is $1.52. The stock is currently 74.2% below its high.